List of Presentations
Incidence of inpatient constipation among migraine patients treated with erenumab: A retrospective cohort study in a US electronic health record database
Hoffman, V. (2020). Incidence of inpatient constipation among migraine patients treated with erenumab: A retrospective cohort study in a US electronic health record database. Cephalagia (Oral presentations), 40(1S), 3–17. Pg. 11
Oral presentation: MTV20-OR-014
Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: Interim results from a real-world multicenter chart-review study of US headache centers
Hoffman, V. (2020). Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: Interim results from a real-world multicenter chart-review study of US headache centers. Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 18
Digital presentation: MTV20-DP-001
Undertreatment of chronic migraine patients in primary care in France, Germany, Italy, Spain and the United Kingdom
Guerrero, V. (2020). Undertreatment of chronic migraine patients in primary care in France, Germany, Italy, Spain and the United Kingdom .Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 33
Digital presentation: MTV20-DP-017
Insights into the personal experience of migraine patients and the positive impact on their quality of life during erenumab treatment
Schuh, K. (2020). Insights into the personal experience of migraine patients and the positive impact on their quality of life during erenumab treatment.Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 33
Digital presentation: MTV20-DP-043
Real-world evidence data reveals the physicians’ perception on erenumab therapy in German headache centers
Koch, M. (2020). Real-world evidence data reveals the physicians’ perception on erenumab therapy in German headache centers.Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 54
Digital presentation: MTV20-DP-044
Patient‐reported outcomes in patients with migraine and prior prophylactic treatment failure: A subgroup analysis from the BECOME study
Pozo-Rosich, P. (2020). Patient‐reported outcomes in patients with migraine and prior prophylactic treatment failure: A subgroup analysis from the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 54
Digital presentation: MTV20-DP-045
Healthcare resource utilisation among migraine patients from the EU5 who have failed previous prophylactic treatments: Findings from the BECOME study
Lucas, C. (2020). Healthcare resource utilisation among migraine patients from the EU5 who have failed previous prophylactic treatments: Findings from the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 56
Digital presentation: MTV20-DP-046
Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-year interim results of the LIBERTY open-label extension study
Reuter, U. (2020). Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-year interim results of the LIBERTY open-label extension study (Digital presentations), 40(1S), 18–110. Pg. 58
Digital presentation: MTV20-DP-047
Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: Results of a 5-year, open-label extension study
Ashina, M. (2020). Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: Results of a 5-year, open-label extension study (Digital presentations), 40(1S), 18–110. Pg. 60
Digital presentation: MTV20-DP-049
Erenumab in episodic and chronic migraine: Post hoc analysis of efficacy data by high versus low-frequency migraine in phase 2 and phase 3 studies
Reuter, U. (2020). Erenumab in episodic and chronic migraine: Post hoc analysis of efficacy data by high versus low-frequency migraine in phase 2 and phase 3 studies (Digital presentations), 40(1S), 18–110. Pg. 62
Digital presentation: MTV20-DP-050
Erenumab is cost-effective for the prevention of episodic and chronic migraine among patients with prior treatment failures in Sweden
Mahon, R. (2020). Erenumab is cost-effective for the prevention of episodic and chronic migraine among patients with prior treatment failures in Swede (Digital presentations), 40(1S), 18–110. Pg. 63
Digital presentation: MTV20-DP-051
Unmet needs in migraine prevention: An Indian perspective
Desai, J. (2020). Unmet needs in migraine prevention: An Indian perspective (Digital presentations), 40(1S), 18–110. Pg. 66
Digital presentation: MTV20-DP-054
Baseline data of a real-world-evidence-study characterizing prescription patterns in episodic and chronic migraine patients starting treatment with erenumab in Germany (SPECTRE)
Gaul, C. (2020). Baseline data of a real-world-evidence-study characterizing prescription patterns in episodic and chronic migraine patients starting treatment with erenumab in Germany (SPECTRE) (Digital presentations), 40(1S), 18–110. Pg. 67
Digital presentation: MTV20-DP-055
Efficacy and safety of erenumab in patients with episodic migraine from the EMPOwER study
Wang, SJ. (2020). Efficacy and safety of erenumab in patients with episodic migraine from the EMPOwER study (Digital presentations), 40(1S), 18–110. Pg. 67
Digital presentation: MTV20-DP-056
Baseline demographics and disease characteristics from the Phase 3 EMPOwER study in patients with episodic migraine in Asia, Middle East and Latin America
Wang, SJ. (2020). Baseline demographics and disease characteristics from the Phase 3 EMPOwER study in patients with episodic migraine in Asia, Middle East and Latin America (Digital presentations), 40(1S), 18–110. Pg. 69
Digital presentation: MTV20-DP-057
Healthcare resource utilisation in migraine patients stratified by prior prophylactic treatment failure, frequency of monthly migraine days and medication overuse: Evidence from the BECOME study
Gaul, C. (2020). Healthcare resource utilisation in migraine patients stratified by prior prophylactic treatment failure, frequency of monthly migraine days and medication overuse: Evidence from the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 71
Digital presentation: MTV20-DP-059
Treatment satisfaction with erenumab in the US from the patient perspective: A crosssectional analysis of the National Health and Wellness Survey data
Pathak, P. (2020). Treatment satisfaction with erenumab in the US from the patient perspective: A crosssectional analysis of the National Health and Wellness Survey data (Digital presentations), 40(1S), 18–110. Pg. 73
Digital presentation: MTV20-DP-060
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and healthcare resource utilisation as migraine prevention in the United States
Tepper, S.J. (2020). Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and healthcare resource utilisation as migraine prevention in the United States (Digital presentations), 40(1S), 18–110. Pg. 90
Digital presentation: MTV20-DP-080
Impact of erenumab on acute medication usage and healthcare resource utilisation among migraine patients: A US claims database study
Tepper, S.J. (2020). Impact of erenumab on acute medication usage and healthcare resource utilisation among migraine patients: A US claims database study (Digital presentations), 40(1S), 18–110. Pg. 97
Digital presentation: MTV20-DP-088
Comorbidities in low and high frequency episodic and chronic migraine: A subgroup analysis of the BECOME study
Watson, D.P.B. (2020). Comorbidities in low and high frequnecy episodic and chronic migraine: A subgroup analysis of the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 97
Digital presentation: MTV20-DP-090
